421. Suchowersky O., Furtado S., Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 1995; 10:337–340.
422. Sakakibara R., Matsuda S., Uchiyama T., et al. The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res. 2003;13:106–108.
423. Mattiasson A., Abrams P., Van Kerrebroeck P., et al. Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU Int. 2002; 89:855–862.
424. Batla A., Phé V., De Min L., et al. Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage? Mov Disord Clin Pract. 2016;3(5):443-451.
425. Reynard J.M., Cannon A., Yang Q., et al. A novel therapy for nocturnal polyuria: a double‐blind randomized trial of frusemide against placebo. Br J Urol 1998; 81:215–218.
426. Zesiewicz, T.A., Evatt, M., Vaughan, C.P., et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Relat. Disord. 2015; 21: 514–520.
427. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Int Med. 2015; 175(3):401–407.
428. Peyronnet, B., Vurture, G., Palma, J.A., et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism Relat. Disord. 2018; 57: 22–26.
429. Wang J., Zhou Z., Cui Y., et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38(1):22-30.
430. Giannantoni A., Rossi A., Mearini E., et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009; 182: 1453– 1457.
431. Giannantoni A., Conte A., Proietti S., et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011; 186(3):960-4.
432. Kulaksizoglu H., Parman, Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. Parkinsonism Relat. Disord. 2010; 16: 531–534.
433. Finazzi‐Agro E., Peppe A., D'Amico A., et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. J Urol. 2003; 169: 1388– 1391.
434. Seif C., Herzog J., van der Horst C., et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004; 55: 118– 120.
435. Kabay S.C., Kabay S., Yucel M., et al. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson’s disease. Neurourol Urodyn. 2009;28(1):62–67.
436. Mobley D.F., Khera M., Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J. 2017; 93(1105):679–685.
437. Hussain I.F., Brady C.M., Swinn M.J., et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001; 71: 371– 374.
438. Zesiewicz T. A., Helal M., Hauser R.A. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2000; 15(2):305–308.
439. Raffaele R., Vecchio I., Giammusso B., et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002; № 41(4): 382–386.
440. Friedman JH. Viewpoint: Challenges in our understanding of neuroleptic induced parkinsonism. Park Relat Disord; 2014;20:1325–8.
441. Susatia F, Fernandez H. Drug-induced parkinsonism. Curr Treat Options Neurol. 2009;11:162–9.
442. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13(1):13–24.
443. Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69(12):1869–79.
444. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51:850–4
445. Marjama-Lyons J., Koller W. Tremor-predominant Parkinson’s disease //Drugs & aging. – 2000. – Т. 16. – №. 4. C. 273-278
446. Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, et al. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm. 2001;108(11):1299–308
447. Bohlega SA, Al-Foghom NB. Drug-induced Parkinson’s disease. Neurosciences. 2013;18(3):215–21.
448. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850–4.
449. Wardlaw J., Debette S., Jokinen H., et al. ESO Guideline on covert cerebral small vessel disease. European Stroke Journal, First Published May 11, 2021,https://doi.org/10.1177/23969873211012132
450. Spence JD. Management of asymptomatic carotid stenosis. Ann Transl Med 2020;8(19):1262. doi: 10.21037/atm-20-975
451. Vizcarra, J.A., Lang, A.E., Sethi, K.D., Espay, A.J., 2015. Vascular parkinsonism: Deconstructing a syndrome. Movement Disorders 30 (7), 886–894.ъ
452. Zijlmans, J. C. M., Katzenschlager, R., Daniel, S. E., Lees, A. J. L. 2004. The L- dopa response in vascular parkinsonism. Journal of Neurology, Neurosurgery & Psychiatry, 75(4), 545-547.